# Retatrutide FAQ: Common Questions Answered from the Trial Record > Retatrutide questions answered from published research — FDA status, mechanism, availability, how trials dosed it, and what the head-to-head vs tirzepatide trial will determine. Answers drawn from the published trial literature. Where the evidence is incomplete, that is said plainly. ## How does retatrutide help regulate blood sugar levels and aid in weight loss? Retatrutide activates three hormone receptors simultaneously — GLP-1 (which suppresses appetite and stimulates glucose-dependent insulin release), GIP (which enhances post-meal insulin secretion and influences fat tissue), and glucagon (which increases energy expenditure). In a 36-week Phase 2 trial in 281 adults with type 2 diabetes, 12 mg retatrutide reduced HbA1c by -2.02% versus -0.01% placebo and body weight by -16.94% versus -3.00% [2]. ## What is retatrutide (GGG tri-agonist / LY3437943) and what is its potential for treating obesity and diabetes? Retatrutide (LY3437943) is an investigational 39-amino-acid synthetic peptide developed by Eli Lilly that simultaneously agonizes GIP, GLP-1, and glucagon receptors — a triple-agonist design. It is not FDA-approved. In a 36-week Phase 2 trial in type 2 diabetes, 12 mg lowered HbA1c by -2.02% and reduced body weight by -16.94% versus placebo [2]. Phase 3 TRIUMPH trials are ongoing; potential approval is contingent on those results. ## What does retatrutide do? Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors in a single molecule. The GLP-1 arm suppresses appetite and improves glucose-dependent insulin secretion. The GIP arm enhances postprandial insulin and modulates fat tissue. The glucagon arm increases energy expenditure and hepatic lipid oxidation. In Phase 2 trials, this combination produced weight reductions up to -24.2% at 48 weeks (obesity) and HbA1c reductions of -2.02% (type 2 diabetes) [1][2]. ## How does retatrutide work? Retatrutide is a single-molecule triple agonist: one compound that engages three receptors at once. The GLP-1 receptor arm slows gastric emptying and activates satiety circuits in the hypothalamus (the brain region that controls hunger). The GIP receptor arm amplifies insulin secretion and affects fat-cell metabolism. The glucagon receptor arm raises thermogenesis (heat and energy production) in the liver. Together, these three mechanisms reduce food intake, improve blood glucose, and increase calorie burning — which explains the larger weight-loss effect observed versus single or dual-receptor agents in Phase 2 trials [1][2][3]. ## How to reconstitute retatrutide? Retatrutide was administered in clinical trials as a ready-made solution formulated for clinical use — not as a lyophilized (freeze-dried) powder requiring reconstitution. No approved formulation with published reconstitution instructions exists. Gray-market research-labeled retatrutide is an unregulated material of unverified identity, purity, and sterility; this site does not provide preparation instructions for unapproved compounds. ## Is retatrutide FDA approved? No. Retatrutide is not FDA-approved and not approved by any regulatory agency as of 2026. It is investigational, currently in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. It does not have an approved indication, labeled dose, or licensed formulation. The FDA has not received or reviewed a New Drug Application for retatrutide as of mid-2026 [7][8][9]. ## When will retatrutide be available? No confirmed timeline for regulatory approval exists. Phase 3 TRIUMPH trials were ongoing as of mid-2026. Assuming successful Phase 3 results and an efficient FDA review, the earliest plausible window for potential approval would be no earlier than 2027-2028 — and approval is not guaranteed. Until Phase 3 data are published and an NDA (New Drug Application) is reviewed, retatrutide will remain investigational [7][8][9]. ## How to take retatrutide? In clinical trials, retatrutide was administered as a subcutaneous injection (injected into the fatty layer beneath the skin) once weekly. Dose escalation schedules were used to manage GI tolerability — starting at lower doses and stepping up over weeks under clinical supervision. Because retatrutide is not approved, there is no patient labeling or prescribing guidance. This site does not provide dosing or administration instructions [1][4]. ## How long does retatrutide take to work? In the Phase 2 obesity trial, body-weight reductions were measurable within the first 4 weeks and became increasingly pronounced over 48 weeks, with the largest changes at the highest dose occurring between weeks 24 and 48 [1]. The ~6-day half-life means steady-state blood levels are reached after approximately 4-5 weeks of once-weekly dosing. A 2025 review characterizes the weight-loss trajectory as accelerated versus prior incretin therapies, but still progressive across the full trial duration [6]. ## Is retatrutide better than tirzepatide? No head-to-head data have been published as of mid-2026. The active-comparator Phase 3 trial NCT06662383 directly compares retatrutide with tirzepatide and will provide the first rigorous answer [9]. Phase 2 weight-loss figures for retatrutide (~24.2% at 48 weeks in obesity [1]) are numerically higher than Phase 3 figures reported for tirzepatide (~22.5% at 72 weeks in obesity), but cross-trial comparisons are unreliable — different populations, different trial durations, different protocols. ## How much retatrutide per week? In Phase 2 trials, the dose range studied was 1, 4, 8, or 12 mg once weekly via subcutaneous injection [1]. Phase 1b used escalating schedules reaching up to 12 mg in the highest cohort [4]. There is no approved weekly dose — these figures describe what was studied in trials, not what should be used. Retatrutide has no approved formulation or dosing guidance. ## How to mix retatrutide with bacteriostatic water? Retatrutide was not reconstituted by trial participants — it was supplied as a prepared formulation for clinical use. No validated protocol for mixing any form of research-labeled retatrutide with bacteriostatic water has been published in the scientific literature. This site does not provide preparation instructions for unregulated, unapproved compounds of unverified identity and purity. ## How to switch from tirzepatide to retatrutide? There is no published clinical protocol for switching between these two compounds, and retatrutide is not available for prescription use. The head-to-head trial NCT06662383 compares the two drugs directly but is ongoing and has not published results [9]. Any transition between investigational or approved GLP-1-class compounds involves pharmacokinetic considerations (overlapping half-lives, GI tolerance management) that require medical supervision — this site does not provide transition guidance. ## Is retatrutide a GLP-3? No — and "GLP-3" is a misnomer. There is no GLP-3 receptor in human physiology. Retatrutide is a triple agonist at three known receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). The "GLP-3" label appears in some community discussions as informal shorthand for the third component of the triple agonism, but it describes no real receptor or pharmacology [3]. ## Is retatrutide available? Not as a prescription medicine. Retatrutide is investigational and not approved anywhere in the world as of 2026. It is accessible only through enrollment in an active clinical trial — the TRIUMPH program trials (NCT05931367, NCT06383390, NCT06662383) — subject to their eligibility criteria. Gray-market research-labeled material of unverified identity, purity, and sterility exists in unregulated channels; this site does not link to vendors or endorse obtaining unapproved compounds outside trials [7][8][9]. ## What is retatrutide used for? In clinical trials, retatrutide has been studied for obesity (NCT05931367), type 2 diabetes [2], metabolic dysfunction-associated steatotic liver disease (MASLD — fatty liver linked to metabolic risk) [5], cardiovascular outcomes, and kidney function [8]. No approved indication exists. A 2025 review characterizes the breadth of metabolic benefit documented so far as spanning weight loss, glucose control, liver-fat reduction, and favorable lipid effects [6]. ## What receptors does retatrutide target? Three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Cryo-EM structural studies confirmed binding at all three, with relative potency of 8.9x native GIP at GIPR, 0.4x native GLP-1 at GLP-1R, and 0.3x native glucagon at GCGR [3]. All three are class-B G-protein-coupled receptors that signal through cAMP/PKA pathways (a chain of chemical signals inside cells that translates hormone binding into metabolic actions). ## Is retatrutide legal? As a drug candidate in Phase 3 trials, retatrutide is legal to study under an approved clinical trial. It is not scheduled as a controlled substance. However, its sale as a research chemical through gray-market channels may violate federal laws governing unapproved drugs under the Federal Food, Drug, and Cosmetic Act — the FDA issued over 50 warning letters to retatrutide vendors in 2025. Legal status varies by country; this site does not provide legal advice. ## How often do you take retatrutide? All clinical trials used a once-weekly subcutaneous injection schedule, consistent with the approximately 6-day plasma half-life established in Phase 1b pharmacokinetics [4]. This is the administration frequency studied in the published literature — not a dosing recommendation. Retatrutide has no approved dosing schedule. ## What is the half-life of retatrutide? Approximately 6 days in human plasma, established in the Phase 1b first-in-human trial [4]. This was achieved by conjugating the peptide backbone with a C20 fatty-diacid chain that binds serum albumin, dramatically slowing renal clearance. The ~6-day half-life is why all Phase 2 and Phase 3 trials use once-weekly subcutaneous dosing. At steady state (after ~4-5 weeks of once-weekly dosing), retatrutide accumulates to approximately 3x the single-dose level. ## How to store retatrutide? The clinical trial formulation was stored under sponsor-specified conditions not fully disclosed in the published papers. No FDA-cleared storage guidance exists for retatrutide because it has no approved formulation. Gray-market research-labeled material has no validated stability data to support any storage recommendation. Refrigeration is standard for peptide-based drugs in clinical settings, but applying that general principle to unverified material of unknown formulation is speculative — this site does not provide preparation or storage guidance for unapproved compounds. ## Is retatrutide the same as Ozempic? No. Retatrutide is a triple agonist (GLP-1R + GIPR + GCGR) developed by Eli Lilly and is not approved. Semaglutide — the active ingredient in several approved GLP-1 medications — is a single GLP-1 receptor agonist developed by Novo Nordisk and is approved for type 2 diabetes and obesity management. The two compounds target overlapping but distinct receptor sets, come from different developers, and have different approval statuses. Retatrutide's Phase 2 weight-loss figures are numerically higher than those seen in semaglutide trials, but the molecules are pharmacologically distinct. ## Retatrutide cost Retatrutide has no approved list price because it is not an approved drug. No commercial formulation, insurer coverage, or manufacturer assistance program exists for it. Gray-market research-labeled material is sold at unregulated prices that are not reported on this site. A potential approved retatrutide's cost would depend on FDA approval, Eli Lilly's commercial pricing decisions, and payor coverage — none of which exist yet. --- A measured reading of the retatrutide trial record — the Phase 2 endpoints set down and cited, the Phase 3 program noted as open, and nothing here prescribed, dispensed, or sold.